Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens

Beth Israel Comprehensive Cancer Center, New York

Memorial Sloan-Kettering Cancer Center, New York

Local Institution, Berlin

Local Institution, Caen

Roswell Park Cancer Institute, Buffalo

University Of Pittsburgh Medical Center, Pittsburgh

Network Office of Research and Innovation, Allentown

Winship Cancer Institute., Atlanta

Local Institution, Toulouse

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Local Institution, Rennes

Henry-Joyce Cancer Center, Nashville

The Ohio State University, Columbus

University Hospitals Cleveland Medical Center, Cleveland

Providence Cancer Institute, Southfield

Local Institution, Cologne

Local Institution, Lucca

Mayo Clinic, Rochester

Local Institution, Livorno

Local Institution, Strasbourg

Local Institution, Pierre-Bénite

Local Institution, Metairie

Oncology Consultants, Pa, Houston

Local Institution, München

Va San Diego Healthcare System, San Diego

Local Institution, Créteil

Local Institution, Villejuif

University Of California Davis Medical Center, Sacramento

Providence Oncology And Hematology, Portland

Oregon Health & Science University, Portland

Tufts Medical Center, Boston

University Of North Carolina At Chapel Hill, Chapel Hill

Local Institution, Terni